Developer docs
API playgroundTry for free, no card

Search company profiles

kopran

Full company profile

uuid0009xv7

Namestring
kopran
Websiteurl
kopran.com
Company typeenum
Private
Founded yearint
1958
Descriptiontext

Kopran is an integrated pharmaceutical manufacturer founded in 1958 and headquartered in Mumbai, India. According to available sources, the company manufactures and supplies pharmaceutical products — including antibiotics — to a horizontal segment of healthcare providers comprising hospitals, pharmacies, and healthcare institutions. Detailed product naming, brand portfolio, manufacturing footprint, and capacity disclosures are not available in the supplied data, limiting visibility into the company's specific therapeutic or formulation mix.

The company generates revenue through the manufacture and sale of pharmaceutical products. FY2026 (year ended March 2026) revenue was Rs 681.42 crore, up 8.23% year-over-year, with Q4 FY2026 revenue of Rs 234.02 crore up 35.77% YoY. However, FY2026 net profit fell 33.26% YoY to Rs 25.73 crore despite the top-line growth, indicating margin compression. Market capitalization stood at Rs 918 crores as of April 2025, and pricing models and revenue mechanics are not publicly disclosed.

In March 2025, Kopran announced a planned merger with Kopran Laboratories Limited to enter the diagnostics market, combining pharmaceutical manufacturing with diagnostics to broaden its healthcare portfolio. Coinciding with the announcement, investor Madhusudan Kela increased his stake from 1.04% to 1.5%. Leadership is anchored by Surendra Somani as Executive Vice Chairman. No AI/ML capabilities, API platforms, or digital product surfaces are evidenced in the available data.

Short descriptiontext

Kopran is an integrated pharmaceutical manufacturer founded in 1958 in Mumbai, India, producing pharmaceutical products including antibiotics for hospitals, pharmacies, and healthcare institutions, with a planned merger into diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, generic drug formulations, antibiotic production, pharmaceutical distribution, diagnostic services
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kopran is an integrated pharmaceutical manufacturer that produces and supplies drug formulations including antibiotics to healthcare providers such as hospitals, pharmacies, and healthcare institutions. The company is expanding its portfolio into the diagnostics segment through a planned merger with Kopran Laboratories Limited, announced in March 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kopran is a pharmaceutical company. According to available sources, the company is set to merge with Kopran Laboratories Limited to expand into the diagnostics market. No specific product names, brands, or detailed product/service offerings are available in the provided source data.

Product and service2 records
1Pharmaceutical formulations (including antibiotics)
CategoryPharmaceutical Manufacturing
Description

Manufactured pharmaceutical drug formulations including antibiotics, supplied to hospitals, pharmacies, and healthcare institutions for patient treatment.

2Diagnostic services (planned via merger)
CategoryDiagnostic Services
Description

Diagnostic services planned for introduction through the merger with Kopran Laboratories Limited, expanding Kopran's healthcare portfolio beyond pharmaceutical manufacturing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Kopran Ltd announced a merger with Kopran Laboratories Limited to expand into the diagnostics market. This strategic merger represents a significant business expansion initiative for Kopran, combining pharmaceutical manufacturing capabilities with diagnostics to create a broader healthcare portfolio.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian pharma manufacturer with a strong anti-infectives and antibiotics franchise plus complex generics. Comparable therapeutic mix and India-based manufacturing footprint.

TypeDirect peer
Description

One of India's largest generic pharmaceutical manufacturers with a broad antibiotics and respiratory portfolio. Direct overlap with Kopran in manufacturing and supplying pharma products to Indian hospitals and pharmacies.

3Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India's largest pharma company by revenue, manufacturing generics and specialty drugs globally. Comparable as a broader incumbent in the same Indian pharma manufacturing space where Kopran competes.

TypeDirect peer
Description

Major Indian manufacturer of generic antibiotics and APIs with significant USFDA-approved capacity. Directly comparable as a peer Indian antibiotic and pharmaceutical manufacturer.

TypeDirect peer
Description

Indian pharma company with a leading antibiotics and anti-infectives portfolio across domestic and international markets. Closely comparable in product mix and scale tier.

TypeDirect peer
Description

Mid-to-large Indian pharma manufacturer with branded generics across therapeutic areas including anti-infectives. Comparable domestic-market manufacturing profile.

TypeDirect peer
Description

India-based pharma company with branded generics, APIs, and anti-infectives, comparable in scale and product mix to Kopran.

TypeBroad incumbent
Description

Large diversified Indian pharmaceutical manufacturer with significant antibiotics, formulations, and APIs businesses. Comparable as a broader incumbent with overlapping antibiotics manufacturing.

TypeBroad incumbent
Description

Major Indian pharma manufacturer with global generic and API operations, including anti-infectives. Comparable as an established incumbent operating in Kopran's manufacturing space at much larger scale.

TypeDirect peer
Description

India-based pharma manufacturer focused on antibiotics and anti-infectives, directly comparable in therapeutic specialization and scale tier to Kopran.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

kopran

Pharmaceutical Manufacturingkopran.com

Kopran is an integrated pharmaceutical manufacturer founded in 1958 in Mumbai, India, producing pharmaceutical products including antibiotics for hospitals, pharmacies, and healthcare institutions, with a planned merger into diagnostics.

What kopran does

Kopran is an integrated pharmaceutical manufacturer founded in 1958 and headquartered in Mumbai, India. According to available sources, the company manufactures and supplies pharmaceutical products — including antibiotics — to a horizontal segment of healthcare providers comprising hospitals, pharmacies, and healthcare institutions. Detailed product naming, brand portfolio, manufacturing footprint, and capacity disclosures are not available in the supplied data, limiting visibility into the company's specific therapeutic or formulation mix.

The company generates revenue through the manufacture and sale of pharmaceutical products. FY2026 (year ended March 2026) revenue was Rs 681.42 crore, up 8.23% year-over-year, with Q4 FY2026 revenue of Rs 234.02 crore up 35.77% YoY. However, FY2026 net profit fell 33.26% YoY to Rs 25.73 crore despite the top-line growth, indicating margin compression. Market capitalization stood at Rs 918 crores as of April 2025, and pricing models and revenue mechanics are not publicly disclosed.

In March 2025, Kopran announced a planned merger with Kopran Laboratories Limited to enter the diagnostics market, combining pharmaceutical manufacturing with diagnostics to broaden its healthcare portfolio. Coinciding with the announcement, investor Madhusudan Kela increased his stake from 1.04% to 1.5%. Leadership is anchored by Surendra Somani as Executive Vice Chairman. No AI/ML capabilities, API platforms, or digital product surfaces are evidenced in the available data.

kopran firmographics

Firmographics
Name
kopran
Website
https://kopran.com
Company type
Private
Founded year
1958
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Kopran is an integrated pharmaceutical manufacturer founded in 1958 in Mumbai, India, producing pharmaceutical products including antibiotics for hospitals, pharmacies, and healthcare institutions, with a planned merger into diagnostics.
Ownership category
akta.pro rank

kopran industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Pharmaceutical manufacturing
  • Generic drug formulations
  • Antibiotic production
  • Pharmaceutical distribution
  • Diagnostic services

Where kopran is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Markets served

kopran business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

kopran product offering

Product offering

Core offering

Kopran is an integrated pharmaceutical manufacturer that produces and supplies drug formulations including antibiotics to healthcare providers such as hospitals, pharmacies, and healthcare institutions. The company is expanding its portfolio into the diagnostics segment through a planned merger with Kopran Laboratories Limited, announced in March 2025.

Product overview

Kopran is a pharmaceutical company. According to available sources, the company is set to merge with Kopran Laboratories Limited to expand into the diagnostics market. No specific product names, brands, or detailed product/service offerings are available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical formulations (including antibiotics) Manufactured pharmaceutical drug formulations including antibiotics, supplied to hospitals, pharmacies, and healthcare institutions for patient treatment.
  • Diagnostic services (planned via merger) Diagnostic services planned for introduction through the merger with Kopran Laboratories Limited, expanding Kopran's healthcare portfolio beyond pharmaceutical manufacturing.

Companies that use kopran

Customer profile

Segments1 record

Ideal customer profiles1 record

kopran technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

kopran partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kopran Laboratories LimitedcoreStrategic or Co-development Partner · 1 April 2025Kopran Ltd announced a merger with Kopran Laboratories Limited to expand into the diagnostics market. This strategic merger represents a significant business expansion initiative for Kopran, combining pharmaceutical manufacturing capabilities with diagnostics to create a broader healthcare portfolio.

Scale indicators5 records

Recent moves3 records

Expansion highlights3 records

kopran competitors and assessment

Company assessment

Direct peers

  • Lupin: Indian pharma manufacturer with a strong anti-infectives and antibiotics franchise plus complex generics. Comparable therapeutic mix and India-based manufacturing footprint.
  • Cipla: One of India's largest generic pharmaceutical manufacturers with a broad antibiotics and respiratory portfolio. Direct overlap with Kopran in manufacturing and supplying pharma products to Indian hospitals and pharmacies.
  • Aurobindo Pharma: Major Indian manufacturer of generic antibiotics and APIs with significant USFDA-approved capacity. Directly comparable as a peer Indian antibiotic and pharmaceutical manufacturer.
  • Alkem Laboratories: Indian pharma company with a leading antibiotics and anti-infectives portfolio across domestic and international markets. Closely comparable in product mix and scale tier.
  • Torrent Pharmaceuticals: Mid-to-large Indian pharma manufacturer with branded generics across therapeutic areas including anti-infectives. Comparable domestic-market manufacturing profile.
  • Glenmark Pharmaceuticals: India-based pharma company with branded generics, APIs, and anti-infectives, comparable in scale and product mix to Kopran.
  • Orchid Pharma: India-based pharma manufacturer focused on antibiotics and anti-infectives, directly comparable in therapeutic specialization and scale tier to Kopran.

Broad incumbents

  • Sun Pharmaceutical Industries: India's largest pharma company by revenue, manufacturing generics and specialty drugs globally. Comparable as a broader incumbent in the same Indian pharma manufacturing space where Kopran competes.
  • Zydus Lifesciences (Cadila Healthcare): Large diversified Indian pharmaceutical manufacturer with significant antibiotics, formulations, and APIs businesses. Comparable as a broader incumbent with overlapping antibiotics manufacturing.
  • Dr. Reddy's Laboratories: Major Indian pharma manufacturer with global generic and API operations, including anti-infectives. Comparable as an established incumbent operating in Kopran's manufacturing space at much larger scale.

Market position

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

kopran social profiles

Digital presence

kopran financial estimates

Financial estimate

Revenue estimate

Valuation estimate

kopran leadership team

Management profile

Number of profiles

Profiles1 record

kopran funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

kopran M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about kopran

What does kopran do?

Kopran is an integrated pharmaceutical manufacturer that produces and supplies drug formulations including antibiotics to healthcare providers such as hospitals, pharmacies, and healthcare institutions. The company is expanding its portfolio into the diagnostics segment through a planned merger with Kopran Laboratories Limited, announced in March 2025.

Is kopran a public or private company?

kopran is a private company. It is classified as public and is currently operating.

When was kopran founded?

kopran was founded in 1958. It employs 501 to 1,000 people.

Where is kopran based?

kopran is headquartered in Mumbai, India, in the Asia region.

Who are kopran's main competitors?

Direct peers on record are Lupin, Cipla, Aurobindo Pharma, Alkem Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals and Orchid Pharma. Broad incumbents are Sun Pharmaceutical Industries, Zydus Lifesciences (Cadila Healthcare) and Dr. Reddy's Laboratories.

Does kopran have an API?

No public API is recorded for kopran.

What industry is kopran in?

kopran's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business StandardKopran soars 10%, rallies 154% in FY27 so far; what's driving pharma stock?Kopran's shares rose 10% to ₹274.60 on Wednesday, with the stock up 154% in FY27 so far. Promoter United Shippers sold 1.2 million shares, reducing its stake to 2.07%. The company expects growth from in-house APIs and new CDMO contracts.Business TodayACME Solar, Kopran, Aegis Vopak: Top stocks to trade — Key levels, target price & stop lossAxis Direct's Rajesh Palviya recommends buying ACME Solar, Kopran, and Aegis Vopak Terminals, citing bullish technicals. Targets are Rs 395, Rs 275-295, and Rs 313-321, with stop-losses at Rs 430-445, Rs 230, and Rs 290 respectively.ScanXKopran declares ₹3 per share dividend, approves board changes at AGMKopran Limited concluded its 67th AGM on August 18, 2026, approving a final dividend of ₹3 per share and appointing Namrata Somani to the board while re-appointing Varun Somani. Shareholders passed all five ordinary resolutions with overwhelming support from both the promoter group and public non-institutional investors. The meeting also saw the adoption of the company's audited financial statements for the fiscal year 2026.Business News TodayKopran Consolidated June 2026 Net Sales at Rs 153.99 crore, up 11.91% Y-o-Y- Moneycontrol.comKopran reported consolidated net sales of Rs 153.99 crore for June 2026, representing an 11.91% year-over-year increase from the previous period. Despite the revenue growth, the company's quarterly net profit declined by 10.05% to Rs 6.70 crore, driven by higher raw material and employee costs.Business News TodayKopran Standalone June 2026 Net Sales at Rs 62.76 crore, up 18.9% Y-o-Y- Moneycontrol.comKopran reported standalone net sales of Rs 62.76 crore for June 2026, marking an 18.9% year-over-year increase from the previous period. The company also saw its quarterly net profit rise by 91.1% to Rs 6.72 crore, driven by a significant expansion in EBITDA to Rs 11.37 crore.Business StandardKopran consolidated net profit declines 10.07% in the June 2026 quarterKopran reported a 10.07% decline in net profit to Rs 6.70 crore for the quarter ended June 2026, compared to Rs 7.45 crore in the same quarter of the previous year. Despite the profit decline, the company's sales rose 13.88% to Rs 153.99 crore from Rs 135.22 crore, while operating profit margin slightly decreased from 10.45% to 10.27%. The divergence between revenue growth and declining profitability indicates rising costs or operational challenges during the quarter.ScanXKopran net profit falls 10% to ₹670.09 lakh in Q1FY26 as margins compressKopran Limited reported a 10% year-on-year decline in consolidated net profit to ₹670.09 lakh for Q1FY26, driven by margin compression as EBITDA margin fell to 11.55% from 12.22%. Revenue grew 13.8% to ₹1,539.94 lakh, but rising material costs weighed on overall profitability. Meanwhile, standalone net profit more than doubled to ₹672.30 lakh, showing divergence between consolidated and standalone performance.AInvestKoprán Ltd June-quarter consolidated profit 67 mln rupeesKopran Ltd reported a consolidated net profit of ₹1,887 lakh for the quarter ended March 31, 2026, representing a 95% increase from ₹968 lakh in the prior-year quarter, with revenue from operations rising to ₹23,402 lakh from ₹17,236 lakh. The company's EBITDA improved significantly to ₹4,057 lakh from ₹1,400 lakh, expanding the EBITDA margin to 17.34% from 8.12% year-on-year. For the full fiscal year, consolidated net profit declined to ₹2,573.12 lakh from ₹3,855.19 lakh despite revenue increasing to ₹68,142.36 lakh, while the Board recommended a dividend of ₹3.00 per equity share and appointed Mrs. Namrata Somani as Additional Director.ScanXKopran Latest Results: Consolidated Revenue ₹68,142 Lakhs, Net Profit ₹2,573 Lakhs in FY26Kopran Limited has reported consolidated revenue of ₹68,142 lakhs and net profit of ₹2,573 lakhs for FY 2025-26, with standalone total revenue growing 11.10% to ₹30,765 lakhs.ScanXKopran fixes Aug 11 record date for dividend paymentKopran Limited has fixed August 11, 2026 as the record date to determine shareholder eligibility for a dividend payment. The dividend distribution remains contingent upon approval by members at the Annual General Meeting scheduled for August 18, 2026, and is subject to tax deducted at source. The announcement is a standard procedural step in the company's dividend distribution process.